Oncoradio Centre Oncogard

Research at Oncoradio Centre Oncogard targets cancers of the digestive tract, aiming to improve treatment effectiveness. Ovarian cancer trials explore new chemotherapy schedules and immunotherapy combinations. Colorectal cancer studies focus on adjuvant strategies for older patients.

• Dose-dense chemotherapy regimens
• Combination of PARP inhibitor with immunotherapy
• Biomarker-driven patient selection
• Neoadjuvant strategies for advanced disease

The site collaborates in multinational studies and emphasizes personalized medicine to tailor therapies for individual patients.

Investigations include blood‑related malignancies, seeking to expand therapeutic options. Acute myeloid leukemia research evaluates novel targeted agents. Myelofibrosis projects assess combination approaches after JAK‑inhibitor failure. Multiple myeloma work examines MRD‑adapted treatment intensification.

• Targeted therapies for high‑risk myelodysplastic syndrome
• Novel JAK‑inhibitor combinations
• Antibody‑drug conjugates for leukemia
• MRD‑guided treatment adaptation

These efforts reflect a commitment to clinical innovation in hematologic oncology.

The department conducts trials on cancers affecting the male urogenital tract. Prostate cancer studies test radioligand therapy and intensified androgen deprivation. Penile carcinoma investigations compare surgical and chemotherapeutic approaches.

• Radioligand therapy for metastatic castration‑resistant prostate cancer
• Combination of androgen deprivation with novel agents
• Surgical and chemotherapeutic approaches for penile cancer
• Biomarker-driven de‑escalation strategies

The program prioritizes patient‑centered care and multidisciplinary coordination.

A broad portfolio addresses solid tumors, with emphasis on innovative systemic therapies. Breast cancer research spans HER2‑positive de‑escalation, ER+/HER2‑low evaluation, and CDK4/6 inhibitor sequencing. Endometrial cancer trials explore immunotherapy combinations for high‑risk disease.

• HER2‑targeted de‑escalation trials
• ER+/HER2‑low therapeutic evaluation
• CDK4/6 inhibitor sequencing after endocrine resistance
• Immunotherapy in triple‑negative breast cancer

The centre integrates advanced diagnostics to refine patient selection and outcome measurement.

Studies focus on molecular markers that guide treatment decisions. Circulating tumor DNA is used to trigger early therapy switches, while minimal residual disease status informs transplant and maintenance strategies.

• ctDNA‑guided treatment switches
• MRD‑adapted transplant strategies
• Biomarker integration in trial design
• Safety monitoring of novel agents

This work exemplifies a move toward precision oncology across multiple tumor types.